Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English


Warning: getimagesize(images/pics/537012-antineoplastics-mabs-is-the.jpg) [function.getimagesize]: failed to open stream: No such file or directory in /var/www/prinsidecom/htdocs/inc/release_details.php on line 330
Health

Antineoplastics mAbs is the Top Therapeutic Class for Cancer Treatment


Print article Print article

2012-12-19 11:07:14 - Amongst the several cancer treatments available, antineoplastics mAbs is the top therapeutic class for cancer treatment, says RNCOS.

As per RNCOS’s new research report entitled, “Cancer Monoclonal Antibodies Market to 2015”, antineoplastics mAbs are the leading drug class for cancer treatment. Four drugs currently dominate the global antineoplastic mAbs market. These include Roche’s Avastin (bevacizumab), MabThera (rituximab), Herceptin (trastuzumab); and BMS/Merck’s Erbitux. Targeted therapeutic action and lower side effects are the main reasons for the large market share of anti-neoplastic mabs for cancer treatment. Development of several mAbs and anti-angiogenics are expected to lower the severity of side effects in future. Vaccines and certain target-oriented cytostatics are also expected to grow robustly in future.

Our research report has found that cancer represents the fastest growing and one of the most attractive therapeutic segments in the global pharmaceutical market. Factors,

such as fast increase in the number of new cancer cases and the emergence of innovative technologies led to create a US$ 21 Billion worldwide market for antineoplastic mAbs in 2011. Research and innovation in the cancer mAb market has been growing exorbitantly and the industry has been witnessing a large number of consolidation activities. The global cancer mAb market is one of the most promising markets and is likely to advance at a CAGR of around 7% during the forecast period (2012-2015) to reach US$ 27 Billion.

The report, which is spread in over 100 pages, investigates and analyzes all the key developments of cancer mAbs’ market throughout the world. It also identifies the possible growth areas in terms of pipeline products and provides an in-depth analysis on the leading drugs under development with reference to their manufacturers and other key details. The report also covers an exhaustive research on the country-level cancer mAbs market and offers a broad overview of the current developments. It also provides future forecasts for the overall industry and key sections/areas on the basis of past trends, challenges, opportunities for expansion and economic and judgmental analysis. Further, the report illustrates about the approved mAbs, along with their recent industry developments to provide a balanced outlook on the potentials of the growing market.

For FREE SAMPLE of this report visit: www.rncos.com/Report/IM375.htm

Some of our Related Reports are:

- Interferon Market Forecast to 2015 ( www.rncos.com/Report/IM431.htm)
- Insulin Market Forecast to 2015 ( www.rncos.com/Report/IM430.htm)
- Human Growth Hormone Market Forecast to 2015 ( www.rncos.com/Report/IM429.htm)
- Erythropoietin Market Forecast to 2015 ( www.rncos.com/Report/IM428.htm)
- Global Biotech API Market Analysis ( www.rncos.com/Report/IM424.htm)

Check Related REPORTS on: www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.





Press Information:
RNCOS E-Services Pvt. Ltd.

B-129, Sector 6 Noida - 201301

Contact Person:
Shushmul Maheshwari
Chief Executive
Phone: 91-120-4224-700
email: email

Web: www.rncos.com

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com